Balancing the genetic risk of APOL1 kidney disease variants

Autor: Kaboré NF; Department of Clinical Research, Centre MURAZ, 2054, avenue Mamadou-Konate, 01 BP 390, Bobo-Dioulasso 01, Burkina Faso., Limou S; Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, Inserm, Université de Nantes, 30, boulevard Jean-Monnet, 44093 Nantes cedex 1, France; Institut de Transplantation en Urologie-Néphrologie (ITUN), CHU Nantes, 30, boulevard Jean-Monnet, 44093 Nantes cedex 1, France; École centrale de Nantes, 1, rue de la Noë, 44300 Nantes, France. Electronic address: sophie.limou@univ-nantes.fr.
Jazyk: francouzština
Zdroj: Nephrologie & therapeutique [Nephrol Ther] 2019 Apr; Vol. 15 Suppl 1, pp. S79-S84.
DOI: 10.1016/j.nephro.2019.03.007
Abstrakt: African-Americans exhibit an excess risk for chronic and end-stage kidney disease compared to the non-African populations. Two APOL1 genetic variants were shown to account for the majority of this racial disparity in glomerulopathies and other non-diabetic kidney disease. The high-risk genotype has only been reported in populations with recent African ancestry (14 % in African-Americans and up to more than 30 % in West Africa). In less than 10 years, the community has accumulated extensive knowledge on APOL1 and its genetic variants, from their positive selection for resistance against African trypanosomes to potential molecular mechanisms of podocyte injury. Finally, APOL1 associations with kidney transplantation outcomes and with postdonation end-stage kidney disease in living donors have paved the way for a personalized medicine implementation of APOL1 genotyping.
(Copyright © 2019 Société francophone de néphrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: